X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare, Analyse Lupin Ltd with TEVA PHARMACEUTICAL INDUSTRIES LTD. - Israel - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

LUPIN vs TEVA PHARMA (Israel) - Comparison Results

LUPIN    Change

Lupin is a leading pharmaceutical company with a strong presence in anti-infective, cardiovascular and asthma. Apart from having a strong domestic presence, the company markets its products in the regulated markets of the US and Europe and semi-regul... More

TEVA PHARMA (Israel)
   Change

Teva Pharmaceuticals, established in 1901, is a global pharmaceutical company. The company is into development, production and marketing of a wide range of specialty medicines, generic and OTC products, active pharmaceutical ingredients (API) and nov... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 LUPIN   TEVA PHARMA
EQUITY SHARE DATA
    LUPIN
Mar-18
TEVA PHARMA
Dec-13
LUPIN/
TEVA PHARMA
5-Yr Chart
Click to enlarge
High Rs1,4652,909-   
Low Rs7272,527-   
Sales per share (Unadj.) Rs349.61,669.4-  
Earnings per share (Unadj.) Rs5.6104.3-  
Cash flow per share (Unadj.) Rs29.6239.2-  
Dividends per share (Unadj.) Rs5.0091.29-  
Dividend yield (eoy) %0.53.4 13.6%  
Book value per share (Unadj.) Rs300.31,854.4-  
Shares outstanding (eoy) m452.08848.00-   
Bonus/Rights/Conversions ESOPS--  
Price / Sales ratio x3.11.6 192.6%   
Avg P/E ratio x197.226.1 756.7%  
P/CF ratio (eoy) x37.111.4 326.2%  
Price / Book Value ratio x3.61.5 249.0%  
Dividend payout %90.087.5 102.8%   
Avg Mkt Cap Rs m495,5022,304,788 21.5%   
No. of employees `00017.044.9 37.9%   
Total wages/salary Rs m28,6470-   
Avg. sales/employee Rs Th9,273.631,498.1 29.4%   
Avg. wages/employee Rs Th1,681.00-   
Avg. net profit/employee Rs Th147.41,967.7 7.5%   
INCOME DATA
Net Sales Rs m158,0421,415,683 11.2%  
Other income Rs m1,5040-   
Total revenues Rs m159,5451,415,683 11.3%   
Gross profit Rs m31,475387,685 8.1%  
Depreciation Rs m10,859114,431 9.5%   
Interest Rs m2,04427,806 7.3%   
Profit before tax Rs m20,076245,448 8.2%   
Minority Interest Rs m-711,115 -6.4%   
Prior Period Items Rs m350-   
Extraordinary Inc (Exp) Rs m-14,644-161,123 9.1%   
Tax Rs m2,885-2,997 -96.3%   
Profit after tax Rs m2,51388,437 2.8%  
Gross profit margin %19.927.4 72.7%  
Effective tax rate %14.4-1.2 -1,176.8%   
Net profit margin %1.66.2 25.4%  
BALANCE SHEET DATA
Current assets Rs m122,095956,147 12.8%   
Current liabilities Rs m50,956833,841 6.1%   
Net working cap to sales %45.08.6 521.0%  
Current ratio x2.41.1 209.0%  
Inventory Days Days8591 93.2%  
Debtors Days Days12096 125.0%  
Net fixed assets Rs m129,876462,393 28.1%   
Share capital Rs m9043,485 25.9%   
"Free" reserves Rs m134,8660-   
Net worth Rs m135,7711,572,555 8.6%   
Long term debt Rs m64,245723,870 8.9%   
Total assets Rs m263,0543,235,289 8.1%  
Interest coverage x10.89.8 110.2%   
Debt to equity ratio x0.50.5 102.8%  
Sales to assets ratio x0.60.4 137.3%   
Return on assets %1.73.6 48.2%  
Return on equity %1.95.6 32.9%  
Return on capital %3.74.9 75.4%  
Exports to sales %00-   
Imports to sales %00-   
Net fx Rs m33,8070-   
CASH FLOW
From Operations Rs m17,512225,587 7.8%  
From Investments Rs m-14,073-79,934 17.6%  
From Financial Activity Rs m-14,921-270,606 5.5%  
Net Cashflow Rs m-11,482-124,954 9.2%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for TEVA PHARMA (Israel) is United States Dollars. All data has been converted at 69.69 Rs / USD

Compare LUPIN With: MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  

Compare LUPIN With: AUROBINDO PHARMA  VENUS REMEDIES  DR. REDDYS LAB  DR. DATSONS LABS  DISHMAN PHARMA  



Today's Market

Indian Indices End on a Strong Note; Sensex Ends 489 Points Higher(Closing)

After opening the day marginally lower, Indian share markets witnessed most of the buying interest during closing hours and ended their trading session on a strong note.

Related Views On News

LUPIN Announces Quarterly Results (4QFY19); Net Profit Down 1.5% (Quarterly Result Update)

May 17, 2019 | Updated on May 17, 2019

For the quarter ended March 2019, LUPIN has posted a net profit of Rs 3 bn (down 1.5% YoY). Sales on the other hand came in at Rs 44 bn (up 77.8% YoY). Read on for a complete analysis of LUPIN's quarterly results.

LUPIN LTD Announces Quarterly Results (3QFY19); Net Profit Down 149.7% (Quarterly Result Update)

Feb 13, 2019 | Updated on Feb 13, 2019

For the quarter ended December 2018, LUPIN LTD has posted a net profit of Rs 2 bn (down 149.7% YoY). Sales on the other hand came in at Rs 45 bn (up 78.0% YoY). Read on for a complete analysis of LUPIN LTD's quarterly results.

LUPIN LTD 2017-18 Annual Report Analysis (Annual Result Update)

Aug 16, 2018 | Updated on Aug 16, 2018

Here's an analysis of the annual report of LUPIN LTD for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of LUPIN LTD. Also includes updates on the valuation of LUPIN LTD.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Lupin: US Markets Drags down Revenues and Net Profits (Quarterly Results Update - Detailed)

Nov 2, 2017

Domestic markets registers robust growth in the quarter

More Views on News

Most Popular

7 Stocks That Will Remain Evergreen in this Era of Technological Disruption(The 5 Minute Wrapup)

Jun 13, 2019

We are living in an era of disruption. Are your stocks well equipped to adapt to changes that disruption will bring along?

The Great Indian NBFC Bubble Has Burst but I Will Still Recommend These Safe NBFCs(The 5 Minute Wrapup)

Jun 11, 2019

One chart that predicted the NBFC crisis back in 2016.

Kenneth Andrade Would Like Our Real Estate Stock Recommendation with Triple Digit Upside(The 5 Minute Wrapup)

Jun 12, 2019

This real estate stock recommended in Smart Money Secrets offers the most favourable upside potential.

Why Modi 2.0 Will Be Great for These 7 Stocks(Profit Hunter)

Jun 10, 2019

The government's focus on Infra, electricity, water for all will be the key factors for Sensex 1,00,000.

Why I Believe Smallcaps Will Catch up to the Sensex(Profit Hunter)

Jun 14, 2019

Smallcaps have gone nowhere even as the Sensex makes new all-time highs. Find out why Richa believes this a good opportunity to invest in smallcaps.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

LUPIN SHARE PRICE


Jun 20, 2019 (Close)

TRACK LUPIN

COMPARE LUPIN WITH

MARKET STATS